Sign in to our online system or register for a new account to submit a letter of intent.
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.
Now in its 5th year, the Canada: Rapid Response 2017 program provides seed funding for high-risk, high-reward, translational research projects on neurodegenerative diseases of aging.
NEW for 2017:
For more information, please refer to the Program Details and Request for Applications (RFA) documents for each program below.
Goal: To provide funding for novel, high-risk, high-reward, translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.
Funding: A maximum of $200,000 over up to 18 months per project.
Applicant Eligibility: Eligible Principal Applicants must be researchers working in Canada at least 30% of the time at or above the level of Postdoctoral Fellow, and affiliated with a Canada Revenue Agency-qualified donee institution located in Canada.
If the Principal Applicant is not appointed at the institution from which they are applying, they need to apply with a research supervisor (an “Administrative Supervisor”) at or above the level of Assistant Professor or equivalent, with an appointment at the institution from which they are applying.
Applicants may appear in any role on any number of LOIs.
Project Eligibility: Projects must meet two conditions to be eligible,
Please refer to Funding Overview for Institute definitions of neurodegenerative diseases of aging, translational research, therapeutic, and tool.
The Rapid Response program will have multiple calls per year, alternating between two different disease groups (outlined below). Applicants should apply to the group best suited to their project.
|AD-related diseases:||PD-related diseases:|
|o Alzheimer’s disease||o Parkinson’s disease|
|o Frontotemporal dementia||o Progressive supranuclear palsy|
|o Mild cognitive impairment||o Dementia with Lewy bodies|
|o Prodromes to the above||o Multiple systems atrophy|
|o Vascular contributions to the above||o Prodromes to the above|
|o Vascular contributions to the above|
The Institute encourages applicants to contact us at email@example.com or +1 (416) 935-4056 with any questions regarding this program, including whether a potential idea is in scope.
There are two stages to the application process: Letters of Intent and Proposals. An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited in July 2017.
Parkinson’s and Related Diseases (CLOSED)
Alzheimer’s and Related Diseases (NOW OPEN)
|Program opens:||Fall 2017||Letter of Intent deadline:||July 5, 2017 at 2:00pm EDT|
|Proposal deadline:||October 19, 2017 at 2:00pm EDT (by invite only)|
|Anticipated award notification:||December 2017|
|*Dates may change|
The Institute will hold a Program Information Webinar to provide further details on the program and answer any questions.
April 4, 2017 at 1:00pm EDT.
June 12, 2017 at 1:00pm EDT. Register here.
The Institute welcomes inquiries about this program or any of our other funding opportunities. Contact us at firstname.lastname@example.org or +1 416-935-4056.